Department of Endocrinology (M.J.O., T.H., T.N.K., B.L.L., S.B.P.), Aarhus University Hospital, 8000 Aarhus, Denmark and Department of Clinical Medicine (M.J.O., S.B.P.), Aarhus University, 8000 Aarhus, Denmark.
J Clin Endocrinol Metab. 2014 Dec;99(12):4720-9. doi: 10.1210/jc.2014-2799.
Metabolic syndrome (MetS) is associated with low-grade inflammation, which may harmfully affect bone. Resveratrol (RSV) possesses anti-inflammatory properties, and rodent studies suggest bone protective effects.
This study sought to evaluate effects of RSV treatment on bone in men with MetS.
The study was conducted at Aarhus University Hospital as a randomized, double-blinded, placebo-controlled trial assessing changes in bone turnover markers, bone mineral density (BMD), and geometry.
The study population comprised 74 middle-aged obese men with MetS recruited from the general community, of which 66 completed all visits. Mean age of participants was 49.3 ± 6.3 years and mean body mass index was 33.7 ± 3.6 kg/m(2).
Oral treatment with 1.000 mg RSV (RSV(high)), 150 mg RSV (RSV(low)), or placebo daily for 16 weeks.
Prespecified primary endpoint was change in bone alkaline phosphatase (BAP).
BAP increased dose dependently with RSV (R = 0.471, P < .001), resulting in a significantly greater increase in BAP in the RSV(high) group compared with placebo at all time-points (week 4, 16.4 ± 4.2%, P < .001; week 8, 16.5 ± 4.1%, P < .001; week 16, 15.2 ± 3.7%, P < .001). Lumbar spine trabecular volumetric bone mineral density (LS vBMD(trab)) also increased dose dependently with RSV (R = 0.268, P = .036), with a significant increase of 2.6 ± 1.3% in the RSV(high) group compared with placebo (P = .043). In addition, changes in BAP and LS vBMD(trab) were positively correlated (R = 0.281, P = .027). No consistent changes were detected in bone density at the hip.
Our data suggest that high-dose RSV supplementation positively affects bone, primarily by stimulating formation or mineralization. Future studies of longer duration comprising populations at risk of osteoporosis are needed to confirm these results.
代谢综合征(MetS)与低度炎症有关,这可能对骨骼造成有害影响。白藜芦醇(RSV)具有抗炎特性,啮齿动物研究表明其具有保护骨骼的作用。
本研究旨在评估 RSV 治疗对患有 MetS 的男性骨骼的影响。
该研究在奥胡斯大学医院进行,是一项随机、双盲、安慰剂对照试验,评估了骨转换标志物、骨密度(BMD)和骨几何形状的变化。
该研究人群由来自普通社区的 74 名中年肥胖男性组成,其中 66 名完成了所有就诊。参与者的平均年龄为 49.3 ± 6.3 岁,平均体重指数为 33.7 ± 3.6 kg/m2。
口服 RSV 1000mg(RSV(高))、150mg(RSV(低))或安慰剂,每日一次,持续 16 周。
预设的主要终点是骨碱性磷酸酶(BAP)的变化。
BAP 与 RSV 呈剂量依赖性增加(R = 0.471,P <.001),RSV(高)组在所有时间点的 BAP 增加均显著大于安慰剂组(第 4 周,16.4 ± 4.2%,P <.001;第 8 周,16.5 ± 4.1%,P <.001;第 16 周,15.2 ± 3.7%,P <.001)。腰椎小梁骨体积密度(LS vBMD(trab))也与 RSV 呈剂量依赖性增加(R = 0.268,P =.036),与安慰剂相比,RSV(高)组的 LS vBMD(trab)增加了 2.6 ± 1.3%(P =.043)。此外,BAP 和 LS vBMD(trab)的变化呈正相关(R = 0.281,P =.027)。在髋部,未检测到骨密度的一致变化。
我们的数据表明,高剂量 RSV 补充剂对骨骼有积极影响,主要通过刺激形成或矿化。需要进行持续时间更长、包含骨质疏松风险人群的研究来证实这些结果。